Overt Hepatic Encephalopathy Drug Pipeline Analysis Report 2024

Report Coverage

The Overt Hepatic Encephalopathy Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into overt hepatic encephalopathy drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for overt hepatic encephalopathy. The report includes the analysis of over 20+ pipeline drugs and 10+ companies. The overt hepatic encephalopathy pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from overt hepatic encephalopathy.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to overt hepatic encephalopathy.

Overt Hepatic Encephalopathy Drug Pipeline Outlook

Overt hepatic encephalopathy is a reversible neurological complication of cirrhosis which is caused by liver dysfunction. This disease affects the central nervous system and affects how a person thinks, feels, and acts. The symptom of overt hepatic encephalopathy varies and ranges from disorientation to erratic behavior and personality changes.

The disorder is caused by neurotoxins (substances which are toxic to the brain and nervous system) in the blood. When the liver doesn’t filter these toxins from the blood, these neurotoxins continue to circulate, eventually entering and affecting the brain. It usually occurs in advanced liver disease when the function of the liver begins to fail. The disorder can affect personality, mood, consciousness, sleep patterns, concentration and thinking, behavior along with impulse control among others.

There are three types of hepatic encephalopathy including type A, type B and type C. Type A is caused by acute liver failure. It is a sudden loss of liver function due to severe liver injury. Type B is caused by a portosystemic shunt when blood flow bypasses its normal route through a new and abnormal passageway and type C is caused by chronic liver failure. The medications given to treat the conditions include rifaximin, and lactulose among others. Rifaximin antibiotic is nonabsorbable by intestines and actulose is a synthetic laxative draws water into the bowel. The supplemental medications given are amino acids to build muscle and clear ammonia from blood and probiotics to encourage healthy gut bacteria to compete with the less helpful types of bacterial which produce neurotoxins. Several pharma companies and research institutes are developing innovative treatment to manage overt hepatic encephalopathy. According to National Institute of Health, several clinical trial studies suggest that rifaximin has shown significant beneficial effect on the improvement of overt hepatic encephalopathy. The increasing clinical trials and changing dynamics are impacting the overt hepatic encephalopathy clinical trial landscape significantly.

Overt Hepatic Encephalopathy – Drug Pipeline Therapeutic Assessment

Overt Hepatic Encephalopathy – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase IV covers a major share of the total clinical trials for overt hepatic encephalopathy.

Overt Hepatic Encephalopathy – Pipeline Assessment Segmentation, By Drug Classes

The drug molecules categories covered under overt hepatic encephalopathy pipeline analysis include peptides, recombinant proteins, and small molecules. L-ornithine and L-aspartate are endogenous amino acids which help with ammonia detoxification. Several trials are suggesting the potential beneficial role of L-ornithine and L-aspartate for the treatment of overt hepatic encephalopathy. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for overt hepatic encephalopathy.

Overt Hepatic Encephalopathy Clinical Trials Therapeutic Assessment – Competitive Dynamics

The EMR report for the overt hepatic encephalopathy drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in overt hepatic encephalopathy clinical trials:

• Bausch Health Americas, Inc.
• Axcella Health, Inc.
• Ocera Therapeutics, Inc.
• Mallinckrodt
• Others

Overt Hepatic Encephalopathy – Emerging Drugs Profile

Leading drugs in the pipeline are as follows:

Drug: 40 mg Rifaximin SSD

The trial is designed to evaluate the safety of Rifaximin Soluble Solid Dispersion tablets and Lactulose for overt hepatic encephalopathy treatment. The trial is sponsored by Bausch Health Americas and is currently under phase II.

Drug: AXA1665

The objective of the study is to compare and assess the safety and tolerability of AXA1665. It is an orally ac...

Drug: Ornithine Phenylacetate

Ocera Therapeutics, Inc. is developing the drug and is currently under phase II. The study is being conducted ...

*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*

Reasons To Buy This Report

The Overt Hepatic Encephalopathy Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for overt hepatic encephalopathy. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within overt hepatic encephalopathy pipeline insights.

Key Questions Answered in the Overt Hepatic Encephalopathy – Pipeline Insight Report

• What is the current landscape of overt hepatic encephalopathy pipeline drugs?
• How many companies are developing overt hepatic encephalopathy drugs?
• How many phase III and phase IV drugs are currently present in overt hepatic encephalopathy pipeline drugs?
• Which companies/institutions are leading the overt hepatic encephalopathy drug development?
• What is the efficacy and safety profile of overt hepatic encephalopathy pipeline drugs?
• What are the opportunities and challenges present in the overt hepatic encephalopathy drug pipeline landscape?
• Which company is conducting major trials for overt hepatic encephalopathy drugs?
• What geographies are covered for overt hepatic encephalopathy clinical trials?
• What are emerging trends in overt hepatic encephalopathy clinical trials?

Related Reports

Hepatic Encephalopathy Treatment Market

Global Hepatic Disease Treatment Market